The sensitizing effect of low‐to‐moderate HMGA2 expression to irinotecan treatment was also demonstrated in patient‐derived xenograft models of human colon cancer, and we mechanistically ascribed these outcomes to a potentiating drug effect in ternary scDNA‐TOP1‐HMGA2 complexes. Here, HMGA2 is linked to malignant colon neoplasm.